Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Refractory Idiopathic Inflammatory Myositis
NCT02347891Phase 3Completed
- Sponsor
- Northwell Health
- Start
- Jan 2015
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in idiopathic inflammatory myopathies (IIM) comparing Belimumab + Standard of Care with Placebo + Standard of Care (2 arms). Primary endpoints: Response Rate During Randomized Phase at 40 weeks and Mean Total Improvement Score During Randomized Phase at 40 weeks. Started Jan 2015; status: completed.
02
Drugs
belimumab
03
Conditions
idiopathic inflammatory myopathies (IIM)
Beyond the preview
Go deeper on NCT02347891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347891.